Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Final Appraisal Recommendation

Advice No: 0921 – May 2021

Conestat alfa (Ruconest®) 2100 U powder and solvent for solution for injection, 2100 U powder for solution for injection

Submission by Pharming Group NV

Recommendation of AWMSG

Conestat alfa (Ruconest®) is recommended as an option for use within NHS Wales for the treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG considered conestat alfa (Ruconest®) as an ultra-orphan equivalent medicine according to the criteria in the AWMSG appraisal process for a medicine for a rare disease.
- The above advice incorporates and replaces the AWMSG recommendation for conestat alfa (Ruconest®) for the treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (advice number 1718, originally published October 2018).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference numbers 4519 and 786), which includes the All Wales Therapeutics and Toxicology Centre (AWTTC) assessment, AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.